36,207 Shares in OR Royalties Inc. $OR Acquired by Navellier & Associates Inc.

Navellier & Associates Inc. bought a new stake in OR Royalties Inc. (NYSE:OR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,207 shares of the basic materials company’s stock, valued at approximately $1,451,000.

A number of other hedge funds and other institutional investors have also modified their holdings of OR. Picton Mahoney Asset Management acquired a new stake in shares of OR Royalties in the 2nd quarter valued at $96,617,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in OR Royalties by 43.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,419,246 shares of the basic materials company’s stock worth $139,006,000 after purchasing an additional 1,648,567 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in OR Royalties during the 3rd quarter worth about $41,210,000. Goldman Sachs Group Inc. lifted its position in OR Royalties by 152.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,256,583 shares of the basic materials company’s stock valued at $26,539,000 after purchasing an additional 758,815 shares during the period. Finally, Manning & Napier Advisors LLC acquired a new position in OR Royalties during the 3rd quarter valued at about $14,998,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

Analyst Upgrades and Downgrades

OR has been the subject of a number of recent research reports. Zacks Research raised shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Canaccord Genuity Group raised shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Wall Street Zen upgraded shares of OR Royalties from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Raymond James Financial raised OR Royalties from a “market perform” rating to an “outperform” rating and set a $41.00 price target on the stock in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of OR Royalties in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, OR Royalties has an average rating of “Buy” and an average target price of $38.25.

OR Royalties Stock Performance

OR opened at $42.98 on Wednesday. The firm’s fifty day moving average is $38.74 and its two-hundred day moving average is $35.50. The firm has a market cap of $8.04 billion, a PE ratio of 54.41 and a beta of 0.76. OR Royalties Inc. has a twelve month low of $17.55 and a twelve month high of $47.75.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.